Literature DB >> 20354178

The antidepressant sertraline inhibits translation initiation by curtailing mammalian target of rapamycin signaling.

Chen-Ju Lin1, Francis Robert, Rami Sukarieh, Stephen Michnick, Jerry Pelletier.   

Abstract

Sertraline, a selective serotonin reuptake inhibitor, is a widely used antidepressant agent. Here, we show that sertraline also exhibits antiproliferative activity. Exposure to sertraline leads to a concentration-dependent decrease in protein synthesis. Moreover, polysome profile analysis of sertraline-treated cells shows a reduction in polysome content and a concomitant increase in 80S ribosomes. The inhibition in translation caused by sertraline is associated with decreased levels of the eukaryotic initiation factor (eIF) 4F complex, altered localization of eIF4E, and increased eIF2alpha phosphorylation. The latter event leads to increased REDD1 expression, which in turn impinges on the mammalian target of rapamycin (mTOR) pathway by affecting TSC1/2 signaling. Sertraline also independently targets the mTOR signaling pathway downstream of Rheb. In the Emu-myc murine lymphoma model where carcinogenesis is driven by phosphatase and tensin homologue (PTEN) inactivation, sertraline is able to enhance chemosensitivity to doxorubicin. Our results indicate that sertraline exerts antiproliferative activity by targeting the mTOR signaling pathway in a REDD1-dependent manner. (c) 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20354178     DOI: 10.1158/0008-5472.CAN-09-4072

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

2.  The DHX33 RNA Helicase Promotes mRNA Translation Initiation.

Authors:  Yandong Zhang; Jin You; Xingshun Wang; Jason Weber
Journal:  Mol Cell Biol       Date:  2015-06-22       Impact factor: 4.272

3.  Everolimus induced mood changes in breast cancer patients: a case-control study.

Authors:  Olivier Mir; Alexandre Salvador; Sarah Dauchy; Stanislas Ropert; Cédric Lemogne; Raphaël Gaillard
Journal:  Invest New Drugs       Date:  2017-12-18       Impact factor: 3.850

4.  The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections.

Authors:  Bing Zhai; Cheng Wu; Linqi Wang; Matthew S Sachs; Xiaorong Lin
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

Review 5.  Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex.

Authors:  Peter Tsai; Mustafa Sahin
Journal:  Curr Opin Neurol       Date:  2011-04       Impact factor: 5.710

Review 6.  Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry.

Authors:  Lisa Cosgrove; Ling Shi; David E Creasey; Maria Anaya-McKivergan; Jessica A Myers; Krista F Huybrechts
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

7.  Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions.

Authors:  Linnéa Schmidt; Teresia Kling; Naser Monsefi; Maja Olsson; Caroline Hansson; Sathishkumar Baskaran; Bo Lundgren; Ulf Martens; Maria Häggblad; Bengt Westermark; Karin Forsberg Nilsson; Lene Uhrbom; Linda Karlsson-Lindahl; Philip Gerlee; Sven Nelander
Journal:  Neuro Oncol       Date:  2013-10-06       Impact factor: 12.300

8.  Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis.

Authors:  Ali A Alhadab; Joshua Rhein; Lillian Tugume; Abdu Musubire; Darlisha A Williams; Mahsa Abassi; Melanie R Nicol; David B Meya; David R Boulware; Richard C Brundage
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-10-04       Impact factor: 2.745

Review 9.  Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation.

Authors:  Peter B Bitterman; Vitaly A Polunovsky
Journal:  Mol Cancer Ther       Date:  2012-05       Impact factor: 6.261

10.  Metabolite profiling of antidepressant drug action reveals novel drug targets beyond monoamine elevation.

Authors:  C Webhofer; P Gormanns; V Tolstikov; W Zieglgänsberger; I Sillaber; F Holsboer; C W Turck
Journal:  Transl Psychiatry       Date:  2011-12-13       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.